Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

1. Hoffman GS, Gross WL. Wegener's granulomatosis: clinical aspects. In: Hoffman GS, Weyand CM, eds. Inflammatory Diseases of Blood Vessels. New York, NY and Basel, Switzerland: Marcel Dekker, Inc, 2002:381-397.

2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2):187-192.

3. Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? Ann Intern Med 2005; 143(9):683-685.

4. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39(1):87-92.

5. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14 (6):555-564.

6. Weiss MA, Crissman JD. Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis. Hum Pathol 1984; 15(10):943-956.

7. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6):488-498.

8. Lebovics RS. Sinonasal complications of vasculitic diseases. Cleve Clin J Med 2002; 69(suppl 2): SII152-SII154.

9. Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener's granulomatosis. Otolaryngol Clin North Am 2003; 36(4):685-705.

10. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41(9):1521-1537.

11. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 2003; 49 (2):151-155.

12. Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56(220):467-483.

13. Lamprecht P, Trabandt A, Gross WL. Clinical and Immunological Aspects of Wegener's Granulomatosis (WG) and other syndromes resembling WG. Isr Med Assoc J 2000; 2(8):621-626.

14. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354(9190):1598-1603. Erratum in Lancet 2000; 356(9224):170. Baycal C [corrected to Baykal C].

15. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114(6):463-469.

16. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349(1):36-44.

17. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52(8):2461-2469.

18. Stegeman CA, Tervaert JW, Sluiter WJ, et al Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120(1):12-17.

19. Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13(1):3—11.

20. Congdon D, Sherris DA, Specks U, et al. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope 2002; 112(4):731-737.

21. Kwan AS, Rose GE. Lacrimal drainage surgery in Wegener's granulomatosis. Br J Ophthalmol 2000; 84(3):329-331.

22. Kornblut AD, Wolff SM, Fauci AS. Ear disease in patients with Wegener's granulomatosis. Laryngoscope 1982; 92(7 Pt 1):713-717.

23. Hoffman GS, Thomas-Golbanov CK, Chan J, et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003; 30(5):1017-1021.

24. Eliachar I, Chan J, Akst L. New approaches to the management of subglottic stenosis in Wegener's granulomatosis. Cleve Clin J Med 2002; 69(suppl 2):SII149-SII151.

25. Langford CA, Sneller MC, Hallahan CW. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39(10):1754-1760.

26. Zakaluzny SA, Lane JD, Mair EA. Complications of tracheobronchial airway stents. Otolaryngol Head Neck Surg 2003; 128(4):478-488.

27. Mair EA. Caution in using subglottic stents for Wegener's granulomatosis. Laryngoscope 2004; 114 (11):2060-2061.

28. Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope 2003; 113(8):1304—1307.

29. Watts RA, Carruthers DM, Scott DJ. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995; 25(1):28-34.

30. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78(1):26-37.

31. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63(2):65-81.

32. Nissim F, Von der Valde J, Czernobilsky B. A limited form of Churg-Strauss syndrome: ocular and cutaneous manifestations. Arch Pathol Lab Med 1982; 106(6):305-307.

33. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108 (2):320-323.

34. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143(9):632-638.

35. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2001; 259-281.

36. Jaffe ES. Pathologic and clinical spectrum of post-thymic T-cell malignancies. Cancer Invest 1984; 2 (5):413-426.

37. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20(1):103-111.

38. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, Nov, 1997. Ann Oncol 1999; 10(12):1419-1432.

39. Chim CS, Ma SY, Au WY. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103(1):216-221.

40. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol 2005; 12 (1):27-34.

41. Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005; 35(1):1-5.

Was this article helpful?

0 0
Natural Arthritis Relief

Natural Arthritis Relief

Natural Arthritis Relief details a unique method of reversing Rheumatoid Arthritis Symptoms by removing numerous arthritis triggers as well as toxins using a simple 5 step natural process.

Get My Free Ebook

Post a comment